Estudo comparativo entre os custos dos tratamentos clínico, cirúrgico ou percutâneo em portadores de doença multiarterial coronária estável - 5 anos de seguimento [tese]. São Paulo: Faculdade de Medicina, Universidade de São Paulo, 2013. INTRODUÇÃO: As principais opções terapêuticas para a doença multiarterial coronária incluem cirurgia de revascularização miocárdica (CRM), intervenção coronária percutânea (ICP) e tratamento clínico (TC). Essas três estratégias terapêuticas apresentam eficácia similar em determinados subgrupos de pacientes. No presente momento, estudos direcionados à análise econômica são escassos, e contemplam, principalmente, os custos comparativos entre as intervenções cirúrgica e percutânea. OBJETIVOS: Analisar, prospectivamente, o custo comparativo das três formas terapêuticas da doença multiarterial coronária estável, durante cinco anos de seguimento. MÉTODOS: Foi computado o custo terapêutico global de 611 pacientes do ensaio clínico The Second Medicine, Angioplasty, or Surgery Study (MASS II), baseado na remuneração provida pelo sistema de saúde suplementar do Instituto do Coração do HC/FMUSP, tomando-se os valores em moeda nacional corrente. Realizou-se, posteriormente, análise de custo-efetividade para o tempo livre de eventos clínicos e o tempo livre de eventos acrescido de tempo livre de angina. RESULTADOS: O TC apresentou 3.79 e 2.07 QALY (quality-adjusted lifeyears); o ICP apresentou 3.59 e 2.77 QALY; e o CRM apresentou 4.4 e 2.81 QALY, respectivamente, para sobrevida livre de eventos e sobrevida livre de eventos e angina. Os custos para sobrevida livre de eventos foram R$ 16.327,80 para TC, R$ 35.940,60 para ICP e R$ 32.873,40 para CRM. A análise pareada dos custos para sobrevida livre de eventos mostrou que houve diferença significante favorecendo TC contra ICP (P < 0,01), e em comparação com CRM (P < 0,01); e CRM versus ICP (P = 0,01). Os custos para sobrevida livre de eventos e angina foram R$ 29.795,40, R$ 46.495,80 e R$ 44.305,20, respectivamente. A comparação pareada dos custos livres de eventos mais livres de angina demonstrou que houve diferença significante favorecendo TC contra ICP (P = 0,04), e em comparação com CRM (P < 0,001). Não houve diferença entre CRM e ICP (P > 0,05). CONCLUSÃO: A análise comparativa entre as diferentes opções terapêuticas desta amostra revelou que TC foi mais custo-efetivo que CRM, e esta, por sua vez, mais custo-efetivo que ICP / BACKGROUND: The therapeutic options for multivessel coronary artery disease are coronary artery bypass graft surgery (CABG), percutaneous coronary intervention (PCI), or medical treatment alone (MT). These three therapeutic strategies present similar efficacy for specific subgroups. At the present moment, economic outcome trials are scant, and contemplate comparative cost between surgical or percutaneous intervention. OBJECTIVE: To analyze, prospectively, the comparative cost from three therapeutic strategies in multivessel coronary artery disease, at 5-year of follow-up. METHODS: We analyzed cumulative costs of 611 patients from clinical trial The Second Medicine, Angioplasty, or Surgery Study (MASS II). The economic analysis is based on remuneration provided by the supplementary health system of the Heart Institute of the Clinical Hospital of FMUSP, expressing these values in Brazilian currency. It was compared to the cumulative costs of each therapeutic strategy in the 5-year follow-up period. A cost-effectiveness analysis was then conducted for event-free survival and event plus angina-free survival. Cost-effectiveness analysis was performed by quality-adjusted life- year (QALY) analysis. RESULTS: Respectively, for event-free survival and event plus angina-free survival, MT presented 3.79 quality-adjusted life-years (QALY) and 2.07 QALY; PCI presented 3.59 and 2.77 QALY; and CABG demonstrated 4.4 and 2.81 QALY. The event-free costs were R$ 16327.80 for MT; R$ 35940.60 for PCI; and R$ 32873.40 for CABG. The paired comparison of the event-free costs showed that there was a significant difference favoring MT versus PCI (P < 0.01) and versus CABG (P < 0.01) and CABG versus PCI (P =0.01). The event-free plus angina-free costs were R$ 29795.40, R$ 46495.80 e R$ 44305.20, respectively. The paired comparison of the event-free plus angina-free costs showed that there was a significant difference favoring MT versus PCI (P =0.04), and versus CABG (P < 0.001); there was no difference between CABG and PCI (P > 0.05). CONCLUSION: The comparative analysis among the different therapeutic strategies demonstrated that MT was more cost-effective than CABG, and this than PCI

Orientador: Robison José Quitério / Resumo: Introdução: Em decorrência do número elevado de comorbidades associadas à Doença Arterial Coronariana (DAC), os modelos de previsão de risco para cirurgia cardíaca foram desenvolvidos com a finalidade de melhor caracterizar os fatores que influenciam os resultados deste procedimento. Além dos escores de risco utilizados mundialmente “European System for Cardiac Operative Risk Evaluation” (EUROSCORE II) e “Society of Thoracic Surgeons” (STS), a Variabilidade da Frequência Cardíaca (VFC) tem surgido como um novo instrumento de previsão do risco cardiovascular e cirúrgico. Objetivo: Caracterizar os pacientes eletivos para cirurgia de revascularização do miocárdio na região de Marília-SP-Brasil, quanto aos fatores de risco e controle neural do coração; Verificar se existe correlação entre os índices da VFC e os escores de risco cirúrgico EUROSCORE II e STS. Amostra: Foi composta por indivíduos de ambos os sexos, acima de 50 anos, eletivos para cirurgia de revascularização do miocárdio (Hospital Santa Casa de Misericórdia de Marília). O Grupo Controle (GC) foi composto por indivíduos de ambos os sexos, acima de 50 anos, saudáveis. Procedimentos do Estudo: Foi realizada a anamnese na qual foram avaliados os fatores de risco para doença cardiovascular. O registro do intervalos RR foi obtido na postura decúbito dorsal, por 20 minutos, em respiração espontânea. Os índices da VFC (lineares e não lineares) foram analisados, comparados com um grupo controle e correlacionados com valores ... (Resumo completo, clicar acesso eletrônico abaixo) / Abstract: Introduction: Due to the high number of comorbidities associated with Coronary Artery Disease (CAD), risk prediction models for cardiac surgery were developed with the purpose of better characterizing the factors that influence the results of this procedure. In addition to the European System for Cardiac Operative Risk Evaluation (EUROSCORE II) and Society of Thoracic Surgeons (STS) worldwide, Heart Rate Variability (HRV) has emerged as a new tool for predicting cardiovascular risk and surgical. Objective: To characterize elective patients for myocardial revascularization surgery in the Marília-SP-Brazil region, regarding risk factors and neural control of the heart; To verify if there is a correlation between the HRV indices and the surgical risk scores EUROSCORE II and STS. Sample: It was composed of individuals of both sexes, over 50 years old, elective for myocardial revascularization surgery (Santa Casa de Misericórdia Hospital of Marília). The Control Group (CG) was composed of individuals of both genders, over 50 years, healthy. Study Procedures: An anamnesis was performed in which the risk factors for cardiovascular disease were evaluated. RR interval recording was obtained in the dorsal decubitus position for 20 minutes in spontaneous breathing. The HRV indices (linear and non-linear) were analyzed, compared to a control group and correlated with values obtained from EUROSCORE II and STS. The data were organized as descriptive statistics, with values of mean and stan... (Complete abstract click electronic access below) / Mestre

Introduction: Cardiovascular surgery is a relatively young but progressively evolving field in medicine. More specifically, in the past decades, cardiac surgery achieved significant advances in understanding the causes, progression and treatments of ischemic heart disease (IHD). The IHD is the most common coronary disease, and it ranks first in morbidity and mortality in the developed world. It justifies the need for significant fundamental research as well as its study in clinical practice. It now includes specialized cardiovascular centres with the complex specialized treatments. A group of interventional cardiologists capable of performing routine examinations of the coronary veins using selective angiography has been established. They can eventually also perform percutaneous coronary interventions with direct stent implants. Thus the advances have been made in comprehensive indication of the patients towards their optimal treatments under the regime of a cardio-team. Such team comprises of a cardio-surgeon, interventional cardiologist, echocardiography specialist and the attending physician who is usually the cardiologist. The IHD treatments involve preventive cardiology with the regime measures and checks, pharmacotherapy, interventional cardiology and cardiac surgery to spa treatment and...

Introduction: Cardiovascular surgery is a relatively young but progressively evolving field in medicine. More specifically, in the past decades, cardiac surgery achieved significant advances in understanding the causes, progression and treatments of ischemic heart disease (IHD). The IHD is the most common coronary disease, and it ranks first in morbidity and mortality in the developed world. It justifies the need for significant fundamental research as well as its study in clinical practice. It now includes specialized cardiovascular centres with the complex specialized treatments. A group of interventional cardiologists capable of performing routine examinations of the coronary veins using selective angiography has been established. They can eventually also perform percutaneous coronary interventions with direct stent implants. Thus the advances have been made in comprehensive indication of the patients towards their optimal treatments under the regime of a cardio-team. Such team comprises of a cardio-surgeon, interventional cardiologist, echocardiography specialist and the attending physician who is usually the cardiologist. The IHD treatments involve preventive cardiology with the regime measures and checks, pharmacotherapy, interventional cardiology and cardiac surgery to spa treatment and...

INTRODUÇÃO: A inflamação atua diretamente na gênese, progressão e manutenção da aterosclerose. A proteína C reativa ultrassensível (PCRus) é um biomarcador inflamatório preditor de eventos cardiovasculares (ECVs). OBJETIVOS: Analisar o comportamento da PCRus na revascularização do miocárdio (RM) com e sem circulação extracorpórea (CEC) nos períodos pré e pós-operatório e correlacioná-los com as variáveis biológicas e laboratoriais. MÉTODOS: Estudo clínico prospectivo não-randomizado, com 136 pacientes pertencentes ao The Medicine, Angioplasty or Surgery Study V (MASS-V Trial) sendo 93 do sexo masculino e 43 do sexo feminino. Foram elencados 69 pacientes para Grupo 1 (G1= RM com CEC) com média de idade de 61,7 anos e 67 pacientes foram elencados para o Grupo 2 (G2= RM sem CEC) com média de idade de 62,6 anos. Todos os participantes do estudo tiveram amostras de sangue coletadas para análise de glicose, triglicérides (TG), creatinina, colesterol total (CT), high density lipoprotein (HDL), low density lipoprotein (LDL) e creatinofosfoquinase (CPK) no pré-operatório. A coleta das amostras de creatinofosfoquinase MB (CKMB), troponina I (TnI) e proteína C reativa ultrassensível (PCRus), foi realizada no pré-operatório e após 6h, 12h, 24h, 36h, 48h e 72h do ato cirúrgico. Também foram obtidas no pré-operatório as variáveis biológicas de cada paciente (idade, tabagismo, diabetes mellitus (DM), lesão de tronco em coronária esquerda (TCE), índice de massa corpórea (IMC), infarto do miocárdio prévio (IAM prévio), fibrose do miocárdio). A presença de fibrose miocárdica foi analisada através de ressonância magnética cardíaca (RMC) 2 dias antes da cirurgia (F1= fibrose pré-operatória) e com 6 dias após a cirurgia (F2= fibrose pós-operatória). A PCRus foi analisada de maneira uni e bivariada com as variáveis laboratoriais e biológicas elencadas para este estudo. Foram incluídos todos os pacientes angiograficamente documentados com estenose multiarterial proximal > 70% e isquemia documentada por teste de esforço (TE) ou classificação de angina estável (Classe II ou III) pela Canadian Cardiovascular Society (CCS). Não foram incluídos neste estudo reoperações, cirurgias combinadas, infarto agudo do miocárdio (IAM) recente ( <= 6 meses), doença inflamatória recente, trombose venosa profunda (TVP) ou tromboembolismo pulmonar recente (TEP), insuficiência renal aguda (IRA) ou insuficiência renal crônica (IRC). RESULTADOS: Os grupos foram considerados comparáveis em função das variáveis biológicas e laboratoriais analisadas, exceto pela maior ocorrência de hipertensão arterial no G1 e de IAM no G2. Observou-se que houve aumento dos valores da PCRus obtidos no pós em relão ao pré-operatório (p < 0,001). Essa alteração foi significativa em relação às técnicas de RM empregadas. Uma análise bivariada correlacionou a área sob a curva da PCRus e as demais variáveis analisadas e não foi observada significância estatística (p > 0,05) com exceção da área sob a curva encontrada da creatinofosfoquinase (CPK) que resultou em uma correlação positiva no G1 (p=0,015). CONCLUSÕES: Houve aumento da PCRus no pós em relação ao pré-operatório. Este aumento ocorreu em todos os momentos avaliados do pós-operatório. Não houve diferença de comportamento da PCRus entre as técnicas de revascularização do miocárdio empregadas / INTRODUCTION: The inflammation acts directly on atherosclerosis genesis, progression and maintenance. Ultrassensitive C- reactive protein (usCRP) is an inflammatory biomarker that predicts cardiovascular events (CVEs). OBJECTIVES: To analyze the behavior of the usPCR in the MR (myocardial revascularization) with and without extracorporeal circulation (ECC) in the pre and postoperative periods and correlate them with the biological and laboratory variables. METHODS: A prospective non-randomized clinical study with 136 patients belonging to The Medicine, Angioplasty or Surgery Study V (MASS-V Trial), 93 males and 43 females. Sixty-nine patients were enrolled for Group 1 (G1 = MR with ECC) with a mean age of 61.7 years and 67 patients were assigned to Group 2 (G2 = MR without ECC) with a mean age of 62.6 years. All participants in the study had blood samples collected to analyse of glucose, triglycerides (TG), creatinine, total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and creatinephosphokinase (CPK) in the preoperative. The samples of creatinephosphokinase MB (CKMB), Troponin I (ITn) and usCRP were collected in the preoperative and after 6, 12, 24, 36, 48, and 72 hours from the surgery. The laboratory analysis provided the usCRP that was analyzed in a univariate and bivariate way. We also analyzed in the preoperative biological variables of each patient (age, smoking, diabetes mellitus (DM), left coronary trunk lesion (LCT), body mass index (BMI), previous myocardial infarction (previous AMI), myocardial fibrosis). The presence of myocardial fibrosis was analyzed by cardiac magnetic resonance imaging (CMR) 2 days before surgery (F1 = preoperative fibrosis) and 6 days after surgery (F2 = postoperative fibrosis). The usCRP was analyzed in a univariate and bivariate way using with the laboratory and biological variables listed for this study. All angiographically documented patients with > 70% proximal multiarterial stenosis and ischemia, documented by stress test (ST) or classification of stable angina (Class II or III), according to the Canadian Cardiovascular Society (CCS), were included. Reoperations, combined surgeries, recent acute myocardial infarction (AMI) ( <=6 months), recent inflammatory disease, deep venous thrombosis (DVT) or recent pulmonary thromboembolism (PTE), acute renal failure (ARF), or chronic renal failure (CRF), were not included. RESULTS: The groups were considered comparable according to the biological and laboratory variables analyzed, except for the greater occurrence of SAH in G1 and AMI in G2. It was observed that there was an increase in the usCRP values obtained in the postoperative period in relation to the preoperative period (p < 0.001). This change was significant in relation to the MR techniques employed. A bivariate analysis correlated the area under the usCRP curve and the other variables analyzed and no statistical significance was observed (p > 0.05) except for the area under the creatine phosphokinase (CPK) curve that resulted in a positive correlation in G1 (p=0.015). CONCLUSIONS: There was an increase in usCRP in the postoperative period compared to the preoperative period. This increase occurred in all moments assessed postoperatively. There was no difference in the usCRP behavior between the two myocardial revascularization techniques employed

Introdução - Os custos para o tratamento da doença arterial coronariana (DAC) são altos em todo o mundo. Foi realizada uma análise post hoc de custo-efetividade de três estratégias terapêuticas para DAC multiarterial. Métodos - De maio de 1995 a maio de 2000, um total de 611 pacientes foram aleatoriamente designados para CRM (n = 203), ICP (n = 205) ou TM (n = 203). Este estudo de análise de custos baseou-se na perspectiva do Sistema Público de Saúde. Os custos iniciais de procedimentos e acompanhamento de medicamentos, exames cardiológicos e hospitalizações por complicações foram calculados após a randomização. Anos de vida e anos de vida ajustados pela qualidade (QALY) foram usados como medidas de eficácia. As razões de custo-efetividade incremental (RCEI) foram obtidas usando métodos de bootstrap não paramétricos com 5.000 replicações. Resultados - Os custos iniciais do procedimento foram menores para o TM. No entanto, os custos acumulados de 5 anos foram menores para a CRM. Em comparação com a linha de base, as 3 opções de tratamento produziram melhorias significativas no QALY. Após 5 anos, a ICP e a CRM tiveram melhores resultados de QALY em comparação com o TM. Os resultados da RCEI favoreceram a CRM e a ICP quando comparadas ao TM, já a ICP em relação à CRM foi mais custo-efetiva em 61% para limiares até 3 PIB per capita por QALY. Por outro lado, a análise de sensibilidade mostrou o TM como a terapia preferida em comparação com a CRM e ICP, na análise considerando custos mais elevados. Conclusão - No seguimento de 5 anos, a ICP e CRM mostraram ser os tratamentos com QALYs cumulativos mais altos entre pacientes com DAC multiarterial quando comparados com TM. Além disso, apesar dos custos iniciais serem mais elevados, a comparação de custo-efetividade após 5 anos de acompanhamento entre os 3 tratamentos mostrou que ambas as intervenções (CRM e ICP) são estratégias custo-efetivas em comparação com a TM / Background. The costs for treating coronary artery disease (CAD) are high worldwide. We performed a post hoc analysis of cost-effectiveness of 3 therapeutic strategies for multivessel CAD. Methods. From May 1995 to May 2000, a total of 611 patients were randomly assigned to CABG (n=203), PCI (n=205), or MT (n=203). This cost analysis study was based on the perspective of the Public Health Care System. Initial procedural and follow-up costs for medications, cardiology examinations, and hospitalizations for complications were calculated after randomization. Life-years and quality-adjusted life years (QALY) were used as effectiveness measures. Incremental cost-effectiveness ratios (ICER) were obtained by using nonparametric bootstrapping methods with 5000 resamples. Results. Initial procedural costs were lower for MT. However, the subsequent 5-year cumulative costs were lower for CABG. Compared with baseline, the 3 treatment options produced significant improvements in QALY. After 5 years, PCI and CABG had better QALY results compared with MT. The ICER results favored CRM and PCI when compared to the TM, since the PCI in relation to the CRM was more costeffective in 61% for the thresholds up to 3 GDP per capita per QALY. On the other hand, sensitivity analysis showed MT as the preferred therapy compared with CABG and PCI, in the analysis considering higher costs. Conclusion. At 5-year follow-up, the 3 treatment options yielded improvements in quality of life, with comparable and acceptable costs. However, despite higher initial costs, the comparison of costeffectiveness after 5 years of follow-up among the 3 treatments showed both interventions (CABG and PCI) to be cost-effective strategies compared with MT

INTRODUÇÃO: A inflamação atua diretamente na gênese, progressão e manutenção da aterosclerose. A proteína C reativa ultrassensível (PCRus) é um biomarcador inflamatório preditor de eventos cardiovasculares (ECVs). OBJETIVOS: Analisar o comportamento da PCRus na revascularização do miocárdio (RM) com e sem circulação extracorpórea (CEC) nos períodos pré e pós-operatório e correlacioná-los com as variáveis biológicas e laboratoriais. MÉTODOS: Estudo clínico prospectivo não-randomizado, com 136 pacientes pertencentes ao The Medicine, Angioplasty or Surgery Study V (MASS-V Trial) sendo 93 do sexo masculino e 43 do sexo feminino. Foram elencados 69 pacientes para Grupo 1 (G1= RM com CEC) com média de idade de 61,7 anos e 67 pacientes foram elencados para o Grupo 2 (G2= RM sem CEC) com média de idade de 62,6 anos. Todos os participantes do estudo tiveram amostras de sangue coletadas para análise de glicose, triglicérides (TG), creatinina, colesterol total (CT), high density lipoprotein (HDL), low density lipoprotein (LDL) e creatinofosfoquinase (CPK) no pré-operatório. A coleta das amostras de creatinofosfoquinase MB (CKMB), troponina I (TnI) e proteína C reativa ultrassensível (PCRus), foi realizada no pré-operatório e após 6h, 12h, 24h, 36h, 48h e 72h do ato cirúrgico. Também foram obtidas no pré-operatório as variáveis biológicas de cada paciente (idade, tabagismo, diabetes mellitus (DM), lesão de tronco em coronária esquerda (TCE), índice de massa corpórea (IMC), infarto do miocárdio prévio (IAM prévio), fibrose do miocárdio). A presença de fibrose miocárdica foi analisada através de ressonância magnética cardíaca (RMC) 2 dias antes da cirurgia (F1= fibrose pré-operatória) e com 6 dias após a cirurgia (F2= fibrose pós-operatória). A PCRus foi analisada de maneira uni e bivariada com as variáveis laboratoriais e biológicas elencadas para este estudo. Foram incluídos todos os pacientes angiograficamente documentados com estenose multiarterial proximal > 70% e isquemia documentada por teste de esforço (TE) ou classificação de angina estável (Classe II ou III) pela Canadian Cardiovascular Society (CCS). Não foram incluídos neste estudo reoperações, cirurgias combinadas, infarto agudo do miocárdio (IAM) recente ( <= 6 meses), doença inflamatória recente, trombose venosa profunda (TVP) ou tromboembolismo pulmonar recente (TEP), insuficiência renal aguda (IRA) ou insuficiência renal crônica (IRC). RESULTADOS: Os grupos foram considerados comparáveis em função das variáveis biológicas e laboratoriais analisadas, exceto pela maior ocorrência de hipertensão arterial no G1 e de IAM no G2. Observou-se que houve aumento dos valores da PCRus obtidos no pós em relão ao pré-operatório (p < 0,001). Essa alteração foi significativa em relação às técnicas de RM empregadas. Uma análise bivariada correlacionou a área sob a curva da PCRus e as demais variáveis analisadas e não foi observada significância estatística (p > 0,05) com exceção da área sob a curva encontrada da creatinofosfoquinase (CPK) que resultou em uma correlação positiva no G1 (p=0,015). CONCLUSÕES: Houve aumento da PCRus no pós em relação ao pré-operatório. Este aumento ocorreu em todos os momentos avaliados do pós-operatório. Não houve diferença de comportamento da PCRus entre as técnicas de revascularização do miocárdio empregadas / INTRODUCTION: The inflammation acts directly on atherosclerosis genesis, progression and maintenance. Ultrassensitive C- reactive protein (usCRP) is an inflammatory biomarker that predicts cardiovascular events (CVEs). OBJECTIVES: To analyze the behavior of the usPCR in the MR (myocardial revascularization) with and without extracorporeal circulation (ECC) in the pre and postoperative periods and correlate them with the biological and laboratory variables. METHODS: A prospective non-randomized clinical study with 136 patients belonging to The Medicine, Angioplasty or Surgery Study V (MASS-V Trial), 93 males and 43 females. Sixty-nine patients were enrolled for Group 1 (G1 = MR with ECC) with a mean age of 61.7 years and 67 patients were assigned to Group 2 (G2 = MR without ECC) with a mean age of 62.6 years. All participants in the study had blood samples collected to analyse of glucose, triglycerides (TG), creatinine, total cholesterol (TC), high density lipoprotein (HDL), low density lipoprotein (LDL) and creatinephosphokinase (CPK) in the preoperative. The samples of creatinephosphokinase MB (CKMB), Troponin I (ITn) and usCRP were collected in the preoperative and after 6, 12, 24, 36, 48, and 72 hours from the surgery. The laboratory analysis provided the usCRP that was analyzed in a univariate and bivariate way. We also analyzed in the preoperative biological variables of each patient (age, smoking, diabetes mellitus (DM), left coronary trunk lesion (LCT), body mass index (BMI), previous myocardial infarction (previous AMI), myocardial fibrosis). The presence of myocardial fibrosis was analyzed by cardiac magnetic resonance imaging (CMR) 2 days before surgery (F1 = preoperative fibrosis) and 6 days after surgery (F2 = postoperative fibrosis). The usCRP was analyzed in a univariate and bivariate way using with the laboratory and biological variables listed for this study. All angiographically documented patients with > 70% proximal multiarterial stenosis and ischemia, documented by stress test (ST) or classification of stable angina (Class II or III), according to the Canadian Cardiovascular Society (CCS), were included. Reoperations, combined surgeries, recent acute myocardial infarction (AMI) ( <=6 months), recent inflammatory disease, deep venous thrombosis (DVT) or recent pulmonary thromboembolism (PTE), acute renal failure (ARF), or chronic renal failure (CRF), were not included. RESULTS: The groups were considered comparable according to the biological and laboratory variables analyzed, except for the greater occurrence of SAH in G1 and AMI in G2. It was observed that there was an increase in the usCRP values obtained in the postoperative period in relation to the preoperative period (p < 0.001). This change was significant in relation to the MR techniques employed. A bivariate analysis correlated the area under the usCRP curve and the other variables analyzed and no statistical significance was observed (p > 0.05) except for the area under the creatine phosphokinase (CPK) curve that resulted in a positive correlation in G1 (p=0.015). CONCLUSIONS: There was an increase in usCRP in the postoperative period compared to the preoperative period. This increase occurred in all moments assessed postoperatively. There was no difference in the usCRP behavior between the two myocardial revascularization techniques employed

Introdução - Os custos para o tratamento da doença arterial coronariana (DAC) são altos em todo o mundo. Foi realizada uma análise post hoc de custo-efetividade de três estratégias terapêuticas para DAC multiarterial. Métodos - De maio de 1995 a maio de 2000, um total de 611 pacientes foram aleatoriamente designados para CRM (n = 203), ICP (n = 205) ou TM (n = 203). Este estudo de análise de custos baseou-se na perspectiva do Sistema Público de Saúde. Os custos iniciais de procedimentos e acompanhamento de medicamentos, exames cardiológicos e hospitalizações por complicações foram calculados após a randomização. Anos de vida e anos de vida ajustados pela qualidade (QALY) foram usados como medidas de eficácia. As razões de custo-efetividade incremental (RCEI) foram obtidas usando métodos de bootstrap não paramétricos com 5.000 replicações. Resultados - Os custos iniciais do procedimento foram menores para o TM. No entanto, os custos acumulados de 5 anos foram menores para a CRM. Em comparação com a linha de base, as 3 opções de tratamento produziram melhorias significativas no QALY. Após 5 anos, a ICP e a CRM tiveram melhores resultados de QALY em comparação com o TM. Os resultados da RCEI favoreceram a CRM e a ICP quando comparadas ao TM, já a ICP em relação à CRM foi mais custo-efetiva em 61% para limiares até 3 PIB per capita por QALY. Por outro lado, a análise de sensibilidade mostrou o TM como a terapia preferida em comparação com a CRM e ICP, na análise considerando custos mais elevados. Conclusão - No seguimento de 5 anos, a ICP e CRM mostraram ser os tratamentos com QALYs cumulativos mais altos entre pacientes com DAC multiarterial quando comparados com TM. Além disso, apesar dos custos iniciais serem mais elevados, a comparação de custo-efetividade após 5 anos de acompanhamento entre os 3 tratamentos mostrou que ambas as intervenções (CRM e ICP) são estratégias custo-efetivas em comparação com a TM / Background. The costs for treating coronary artery disease (CAD) are high worldwide. We performed a post hoc analysis of cost-effectiveness of 3 therapeutic strategies for multivessel CAD. Methods. From May 1995 to May 2000, a total of 611 patients were randomly assigned to CABG (n=203), PCI (n=205), or MT (n=203). This cost analysis study was based on the perspective of the Public Health Care System. Initial procedural and follow-up costs for medications, cardiology examinations, and hospitalizations for complications were calculated after randomization. Life-years and quality-adjusted life years (QALY) were used as effectiveness measures. Incremental cost-effectiveness ratios (ICER) were obtained by using nonparametric bootstrapping methods with 5000 resamples. Results. Initial procedural costs were lower for MT. However, the subsequent 5-year cumulative costs were lower for CABG. Compared with baseline, the 3 treatment options produced significant improvements in QALY. After 5 years, PCI and CABG had better QALY results compared with MT. The ICER results favored CRM and PCI when compared to the TM, since the PCI in relation to the CRM was more costeffective in 61% for the thresholds up to 3 GDP per capita per QALY. On the other hand, sensitivity analysis showed MT as the preferred therapy compared with CABG and PCI, in the analysis considering higher costs. Conclusion. At 5-year follow-up, the 3 treatment options yielded improvements in quality of life, with comparable and acceptable costs. However, despite higher initial costs, the comparison of costeffectiveness after 5 years of follow-up among the 3 treatments showed both interventions (CABG and PCI) to be cost-effective strategies compared with MT

No description available.

<p>Ishemijska bolest srca najče&scaron;će nastaje kao posledica razvoja aterosklerotskih promena na koronarnim krvnim sudovima koji dovode do suženja lumena i posledičnog pada protoka arterijske krvi u području vaskularizacije. Akutni oblik koronarne bolesti koji zahteva hitnu primenu reperfuzione terapije je ST elevirani infarkt miokarda. EKG ima veliki značaj u postavljanju dijagnoze ali i u proceni uspe&scaron;nosti same reperfuzije. &Scaron;irina QRS kompleksa jedan je od EKG parametara čija dinamika promena može ukazati na uspe&scaron;nost pPKI i veličinu infarktne zone. Evaluacija &scaron;irine QRS kompleksa kao prediktora veličine infarkta miokarda i reperfuzije nakon pPKI kod pacijenata sa STEMI. Ispitivanje je sprovedeno kao prospektivna, opservaciona klinička studija na Klinici za kardiologiju, Instituta za kardiovaskularne bolesti Vojvodine u periodu od januara 2016. do decembra 2018. godine. U isptivanje je uključeno 200 pacijenata sa STEMI kod kojih je urađena pPKI. Na osnovu dužine trajanja tegoba formirane su dve grupe od po 100 pacijenata. Grupa A kod kojih je totalno ishemijsko vreme bilo &lt;6h i grupa B kod kojih je totalno ishemijsko vreme između 6 i 12h. . Sprovedeno je EKG praćenje radi procene &scaron;irine QRS kompleksa intrahospitalno (pre procedure, odmah nakon pPKI kao i posle 1h i 72h) i na dve vizite ambulantno tokom &scaron;estomesečnog praćenja (nakon mesec dana i &scaron;est meseci). Ehokardiografija je urađena kod svih pacijenata intrahospitalno i na &scaron;estomesečnom ambulantnom pregledu. &Scaron;irine QRS kompleksa su korelirane sa rezultatima interventne procedure procenjene TIMI protokom i TMPG, dinamikom kardiospecifičnih enzima i ehokardiografskim nalazima. U istraživanje je uključeno 71% mu&scaron;karaca i 29% žena, prosečna starost uzorka iznosila je 60.6&plusmn;11.39. Dužina trajanja tegoba značajno se razlikovala između grupa. U grupi A tegobe su trajale prosečno 120 minuta (90-180), dok su u grupi B trajale 420 minuta (360-600) (p&lt;0.0005). DTB nije se značajno razlikovao, 42 minuta (31-54.5) u odnosu na 40.5 minuta (34.5-55) (p=0.818). Prosečna &scaron;irina QRS kompeksa na EKG-u pre pPKI nije se značajno razlikovala između grupa, 100 msec (90-110) u odnosu na 100 msec (93-110) (p=0.308). Nakon reperfuzije uočena je značajna razlika u &scaron;irini QRS kompleksa između grupa na svim intrahospitalnim kao i EKG-ima načinjenim tokom perioda praćenja. QRS kompleks je &scaron;iri kod pacijenata iz grupe B (p&lt;0.0005). Pacijenti iz grupe A koji su imali prohodnu infarktnu arteriju sa TIMI 3 protokom pre implantacije stenta imali su značajno uži QRS kompleks na incijilanom EKG-u u odnosu na pacijente kod kojih je IRA bila sub/okludirana sa TIMI protokom &le;2 (p=0.001). U grupi B prohodna infarktna arterija sa TIMI 3 protokom nije značajno uticala na &scaron;irinu QRS kompleksa na inicijalnom EKG-u (p=0.144). Na EKG-ima nakon procedure QRS kompleks bio je značajno &scaron;iri kod pacijenata kod kojih je TIMI protok &le;2, ali samo za grupu pacijenata koja se javila unutar 6h od početka tegoba (p=0.001). QRS kompleks kod pacijenata koji su se javili nakon 6h od početka tegoba jeste bio uži, ali bez statistički značajne razlike (p=0.336). Pearsonovim testom registrovano je postojanje negativne korelacije &scaron;irine QRS kompleksa i istisne frakcije leve komore, ali i pozitivne korelacije sa WMSI i indeksiranim end sistolnim i end dijastolnim volumenom. ROC analizom pokazano je da ukoliko je QRS kompleks &scaron;iri od 89 msec nakon mesec dana, 8.5 puta je veći rizik od snižene EF na &scaron;estomesečnoj kontroli (p&lt;0.0005, AUC=0.808, cut-off=89msec.). ROC analiza pokazala je i da ukoliko je QRS kompleks &scaron;iri od 99msec 1h nakon procedure, 5 puta je veći rizik od pojave MACE (p&lt;0.0005, AUC=0.744, cut-off=99msec). Izvedena su dva matematička modela zasnovana na &scaron;irini QRS kompleksa koja vr&scaron;e predikciju snižene EF i pojave MACE tokom perioda praćenja. &Scaron;irina QRS kompleksa je pokazatelj reperfuzije kod pacijenata sa STEMI kod kojih se načini revaskularizacija unutar 6h od nastanka tegoba. &Scaron;irina QRS kompleksa mesec dana nakon STEMI predstavlja nezavisni prediktor snižene EF. Pro&scaron;irenje preko 89msec 8.5 povećava rizik od snižene EF. &Scaron;irina QRS kompleksa jedan sat nakon pPKI predstavlja nezavisni prediktor za MACE. Pro&scaron;irenje preko 99msec 5 puta povećava rizik od neželjenog kardiolo&scaron;kog događaja. Izvedena su dva matematička modela koja koriste &scaron;irinu QRS kompleksa i sa visokom precizno&scaron;ću vr&scaron;e predikciju MACE-a, odnosno snižene EF nakon &scaron;est meseci.&nbsp;</p> / <p>Ischemic heart disease most commonly occurs as a result of the atherosclerotic changes in the coronary vessels that lead to the narrowing of the lumen and consequent fall in arterial blood flow in the vascularization area. An acute form of coronary artery disease requiring immediate reperfusion therapy is ST-elevation myocardial infarction. The ECG is of great importance not only in making the diagnosis but also in evaluating the success of the reperfusion itself. The duration of the QRS complex is one of the ECG parameters whose change in dynamics can indicate the success of pPCI as well as the size of the infarct zone. Evaluation of the width of the QRS complex as a predictor of myocardial infarction size and reperfusion after pPCI in patients with STEMI. The study was conducted as a prospective, observational clinical study at the Cardiology Clinic of the Institute of Cardiovascular Diseases of Vojvodina between January 2016 and December 2018. The study included 200 patients with STEMI in whom pPCI was performed. Based on the length of discomforts two groups with 100 patients were formed. Group A had a total ischemic time &lt;6h and the total ischemic time in group B was between 6-12h. To assess the duration of the QRS complex, the ECG monitoring was performed intrahospital (before the procedure, immediately after pPCI as well as 1h and 72h after the procedure) and on two outpatient visits during the six-month follow-up period (after one month and six months). Echocardiography was performed in all patients intrahospital and at a six-month outpatient visit. The duration of the QRS complex correlated with the results of the interventional procedure that was evaluated by the TIMI flow and TMPG, the dynamics of cardiospecific enzymes and echocardiography findings. The survey included 71% of men and 29% of women with an average age of 60.6 &plusmn; 11.39. The duration of the discomforts varied significantly between the groups. In group A the discomforts lasted 120 minutes in an average (90-180), while they lasted 420 minutes in group B (360-600) (p &lt;0.0005). DTB did not differ significantly, 42 minutes (31-54.5) versus 40.5 minutes (34.5-55) (p = 0.818). The average duration of the QRS complex on the ECG before pPCI did not differ significantly between the groups, 100 msec (90-110) versus 100 msec (93-110) (p = 0.308). After the reperfusion, a significant difference in the duration of the QRS complex was observed between the groups at all intrahospital ECGs and the ECGs performed during the follow-up period. The QRS complex was broader in group B patients (p &lt;0.0005). Group A patients who had a patent infarct artery with TIMI 3 flow before the stent implantation had a significantly narrower QRS complex on the initial ECG compared to the patients whose IRA was sub / occluded with TIMI flow &le;2 (p = 0.001). In group B, the patent infarct artery with TIMI 3 flow did not significantly affect the duration of the QRS complex at the initial ECG. (p = 0.144). At the post-procedural ECGs the QRS complex was significantly broader in patients with TIMI flow &le;2, but only in the group of patients who arrived within 6 h from the onset of discomforts (p = 0.001). The QRS complex in patients who arrived 6 h after the onset of discomforts was narrower but without statistically significant difference (p = 0.336). The Pearson test registered the existence of a negative correlation of the QRS complex width and the left ventricular ejection fraction, but also a positive correlation with the WMSI and index end-systolic and end-diastolic volumes. The ROC analysis showed that if the QRS complex was wider than 89 msec after one month, there was an 8.5 times higher risk of decreased EF at the six-month control examination (p &lt;0.0005, AUC = 0.808, cut-off = 89msec.). The ROC analysis also showed that if the QRS complex was wider than 99msec 1h after the procedure, there was a 5 times higher risk of MACE (p &lt;0.0005, AUC = 0.744, cut-off = 99msec). Two mathematical models based on the width of the QRS complex were derived that predicted the lowered EF and the occurrence of MACE during the monitored period. The width of the QRS complex is an indicator of reperfusion in patients with STEMI who undergo revascularization within 6 hours from the onset of discomforts. The width of the QRS complex one month after STEMI is an independent predictor of decreased EF. Broadening over 89msec increases the risk of lowered EF for 8.5 times. The width of the QRS complex one hour after pPCI represents an independent predictor of MACE. Broadening over 99msec increases the risk of an adverse cardiac event 5 times. Two mathematical models have derived that use the width of the QRS complex and predict MACE with high precision as well as reduced EF after six months.</p>